Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otola… Read more
Maxigen Biotech Inc (1783) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.055x
Based on the latest financial reports, Maxigen Biotech Inc (1783) has a cash flow conversion efficiency ratio of 0.055x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$81.78 Million) by net assets (NT$1.47 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Maxigen Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Maxigen Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Maxigen Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maxigen Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Reinet Investments SCA
JSE:RNI
|
0.000x |
|
Midas Minerals Ltd
AU:MM1
|
-0.189x |
|
Payfare Inc
OTCQX:PYFRF
|
0.084x |
|
Creative Newtech Limited
NSE:CREATIVE
|
-0.268x |
|
U-Media Communications
TWO:6470
|
-0.018x |
|
Banyan Gold Corp
OTCQB:BYAGF
|
-0.010x |
|
Kpx Holdings
KO:092230
|
0.002x |
|
FarmStory Co. Ltd
KQ:027710
|
0.034x |
Annual Cash Flow Conversion Efficiency for Maxigen Biotech Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of Maxigen Biotech Inc from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.38 Billion | NT$298.22 Million | 0.217x | +72.42% |
| 2023-12-31 | NT$1.36 Billion | NT$171.20 Million | 0.126x | -39.27% |
| 2022-12-31 | NT$1.30 Billion | NT$268.34 Million | 0.207x | +101.08% |
| 2021-12-31 | NT$1.14 Billion | NT$117.59 Million | 0.103x | +19.10% |
| 2020-12-31 | NT$860.23 Million | NT$74.39 Million | 0.086x | -22.02% |
| 2019-12-31 | NT$851.32 Million | NT$94.42 Million | 0.111x | -45.19% |
| 2018-12-31 | NT$842.98 Million | NT$170.58 Million | 0.202x | +291.31% |
| 2017-12-31 | NT$796.25 Million | NT$41.18 Million | 0.052x | +16.39% |
| 2016-12-31 | NT$781.38 Million | NT$34.72 Million | 0.044x | +133.57% |
| 2015-12-31 | NT$829.86 Million | NT$-109.85 Million | -0.132x | -703.35% |
| 2014-12-31 | NT$877.01 Million | NT$-14.45 Million | -0.016x | +34.46% |
| 2013-12-31 | NT$888.39 Million | NT$-22.34 Million | -0.025x | -155.33% |
| 2012-12-31 | NT$385.66 Million | NT$17.53 Million | 0.045x | +121.89% |
| 2011-12-31 | NT$369.25 Million | NT$-76.64 Million | -0.208x | -389.53% |
| 2010-12-31 | NT$395.39 Million | NT$-16.76 Million | -0.042x | -168.87% |
| 2009-12-31 | NT$313.03 Million | NT$19.27 Million | 0.062x | -- |